Nivolumab Can Trigger Deadly Cytokine Storm, Largest Case Review Finds
A retrospective review of 35 published cases shows that nivolumab can trigger cytokine release syndrome weeks to months into treatment, ...
A retrospective review of 35 published cases shows that nivolumab can trigger cytokine release syndrome weeks to months into treatment, ...
A revised meta-analysis of six phase III trials shows first-line PD-1 inhibitor plus chemotherapy reduces the risk of death by ...
A high tumor mutational burden detected by liquid biopsy guided nivolumab treatment that produced a durable complete remission in a ...
A large UK pan-cancer study finds no consistent link between the season of checkpoint inhibitor initiation and overall survival, despite ...
Highlighted studies at the 2026 ASTRO Annual Meeting in Boston span hypofractionated radiotherapy trials, proton versus photon therapy for liver ...
A sweeping 2024–2025 evidence review shows immune checkpoint inhibitors, frailty-adapted surgery, and artificial intelligence converging to transform esophageal cancer treatment ...
A propensity score matched study from Taiwan finds that adding the immunotherapy drug nivolumab to definitive chemoradiotherapy tripled median overall ...
Researchers in Leipzig corrected a hidden error in a Bayesian network and found the transparent AI model matched real tumor ...
A phase 2 trial found that the HDAC inhibitor entinostat combined with nivolumab produced no tumor responses in advanced cholangiocarcinoma, ...
A systematic review of 116 case reports reveals that immune checkpoint inhibitors can trigger rare but often fatal heart complications, ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine